GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is now gaining a prominent focus in therapeutic studies, largely due to its impressive impact on controlling ailments such as second type diabetes and weight gain. New trials have shown that in addition to glucose regulation, GLP-1 agonists offer potential for cardiovascular well-being and